Georgetown University Selected as REPRIEVE Trial Site


May 12, 2015

Photo of Princy Kumar

Georgetown University, one of the member institutions of the DC D-CFAR, has been selected to serve as a REPRIEVE Trial site (AIDS Clinical Trials Group 5332/5333s). Dr. Princy Kumar, MD will serve as the Principal Investigator of the Georgetown Site. Dr. Kumar is the Director of the DC D-CFAR Clinical and Population Sciences Core, as well as Chief of Infectious Diseases and Professor of Medicine and Microbiology at Georgetown University Medical Center. The REPRIEVE Trial is supported by the National Heart, Lung and Blood Institute (NHLBI), the National Institute of Allergy and Infectious Disease (NIAID) and Kowa Pharmaceuticals. The REPRIEVE trial is the first large scale randomized clinical trial to test a strategy for heart disease prevention among people living with HIV. More information about the REPRIEVE Trial can be found at their website.